Aspirin and Regorafenib

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using regorafenib together with aspirin may increase the risk of bleeding. In clinical studies, treatment with regorafenib alone has been associated with severe and sometimes fatal hemorrhage. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you experience any unusual bleeding or bruising, or have other signs and symptoms of bleeding such as dizziness; lightheadedness; red or black, tarry stools; coughing up or vomiting fresh or dried blood that looks like coffee grounds; severe headache; and weakness. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR CLOSELY: Coadministration of regorafenib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with regorafenib is associated with a high frequency of hemorrhage and thrombocytopenia. In one study, the overall incidence of hemorrhage (grades 1 to 5) was 21% in regorafenib-treated patients compared to 8% in placebo-treated patients, and the incidence of thrombocytopenia was 41% versus 17%. Fatal hemorrhage occurred in 4 of 500 (0.8%) patients receiving regorafenib and involved the respiratory, gastrointestinal, or genitourinary tracts.

GENERALLY AVOID: Coadministration of regorafenib with strong UGT1A9 inhibitors such as mefenamic acid or diflunisal may theoretically increase systemic exposure to regorafenib.

MANAGEMENT: Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with regorafenib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. According to European labeling, concomitant use of regorafenib with mefenamic acid or diflunisal should be avoided.

Aspirin

Generic Name: aspirin

Brand name: Arthritis Pain, Aspir 81, Aspir-Low, Bayer Childrens Aspirin, Durlaza, Ecotrin, Ecpirin, Fasprin, Halfprin, Miniprin, Aspiritab, Bayer, Bayer Low Strength, Bayer Children's, St. Joseph 81 mg Adult

Synonyms: n.a.

What is Aspirin?

Regorafenib

Generic Name: regorafenib

Brand name: Stivarga

Synonyms: n.a.

What is Regorafenib?